These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 1279832)

  • 1. Platelet factor XIII increases the fibrinolytic resistance of platelet-rich clots by accelerating the crosslinking of alpha 2-antiplasmin to fibrin.
    Reed GL; Matsueda GR; Haber E
    Thromb Haemost; 1992 Sep; 68(3):315-20. PubMed ID: 1279832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promotion of the crosslinking of fibrin and alpha 2-antiplasmin by platelets.
    Hevessy Z; Haramura G; Boda Z; Udvardy M; Muszbek L
    Thromb Haemost; 1996 Jan; 75(1):161-7. PubMed ID: 8713796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrin-fibrin and alpha 2-antiplasmin-fibrin cross-linking by platelet factor XIII increases the resistance of platelet clots to fibrinolysis.
    Reed GL; Matsueda GR; Haber E
    Trans Assoc Am Physicians; 1991; 104():21-8. PubMed ID: 1845147
    [No Abstract]   [Full Text] [Related]  

  • 4. Rapid dissociation of platelet-rich fibrin clots in vitro by a combination of plasminogen activators and antiplatelet agents.
    Lam SC; Dieter JP; Strebel LC; Taylor TM; Muscolino G; Feinberg H; Le Breton GC
    J Pharmacol Exp Ther; 1991 Dec; 259(3):1371-8. PubMed ID: 1762085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet-associated factor XIII in platelet activation, adhesion, and clot stabilization.
    Devine DV; Bishop PD
    Semin Thromb Hemost; 1996; 22(5):409-13. PubMed ID: 8989824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Release of alpha 2-plasmin inhibitor from plasma fibrin clots by activated coagulation factor XIII. Its effect on fibrinolysis.
    Mimuro J; Kimura S; Aoki N
    J Clin Invest; 1986 Mar; 77(3):1006-13. PubMed ID: 2419360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A monoclonal antibody against a peptide sequence of fibrinogen gamma chain acts as an inhibitor of factor XIII-mediated crosslinking of human fibrin.
    Taubenfeld SM; Song Y; Sheng D; Ball EL; Matsueda GR
    Thromb Haemost; 1995 Sep; 74(3):923-7. PubMed ID: 8571322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clot retraction increases clot resistance to fibrinolysis by condensing alpha 2-plasmin inhibitor crosslinked to fibrin.
    Aoki N
    Thromb Haemost; 1993 Aug; 70(2):376. PubMed ID: 8236154
    [No Abstract]   [Full Text] [Related]  

  • 9. Determinants of substrate specificity for factor XIII.
    McDonagh J; Fukue H
    Semin Thromb Hemost; 1996; 22(5):369-76. PubMed ID: 8989819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-linking of alpha 2-antiplasmin to fibrin is a key factor in regulating blood clot lysis: species differences.
    van Giezen JJ; Minkema J; Bouma BN; Jansen JW
    Blood Coagul Fibrinolysis; 1993 Dec; 4(6):869-75. PubMed ID: 7511944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rheological properties of fibrin clots. Effects of fibrinogen concentration, Factor XIII deficiency, and Factor XIII inhibition.
    Glover CJ; McIntire LV; Brown CH; Natelson EA
    J Lab Clin Med; 1975 Oct; 86(4):644-56. PubMed ID: 1176815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of factor XIIIa activity on human whole blood clot lysis in vitro.
    Jansen JW; Haverkate F; Koopman J; Nieuwenhuis HK; Kluft C; Boschman TA
    Thromb Haemost; 1987 Apr; 57(2):171-5. PubMed ID: 2440124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban.
    Varin R; Mirshahi S; Mirshahi P; Klein C; Jamshedov J; Chidiac J; Perzborn E; Mirshahi M; Soria C; Soria J
    Thromb Res; 2013 Mar; 131(3):e100-9. PubMed ID: 23313382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compaction of fibrin clots reveals the antifibrinolytic effect of factor XIII.
    Rijken DC; Abdul S; Malfliet JJ; Leebeek FW; Uitte de Willige S
    J Thromb Haemost; 2016 Jul; 14(7):1453-61. PubMed ID: 27148673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defective alpha-polymerization in the conversion of fibrinogen Baltimore to fibrin.
    Brown CH; Crowe MF
    J Clin Invest; 1975 Jun; 55(6):1190-4. PubMed ID: 1133167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking.
    Beckman JD; Holle LA; Wolberg AS
    J Thromb Haemost; 2018 Jan; 16(1):131-141. PubMed ID: 29080382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RGDFAP: platelet aggregation inhibitory and profibrinolytic hybrid peptide (RGDF coupled with the carboxy terminal part of alpha 2-antiplasmin) enhances plasminogen binding to platelets.
    Udvardy M; Schwartzott D; Jackson K; Posan E; Rak K; McKee PA
    Blood Coagul Fibrinolysis; 1995 Jul; 6(5):481-5. PubMed ID: 8589217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The roles of alpha 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis.
    Robbie LA; Booth NA; Croll AM; Bennett B
    Thromb Haemost; 1993 Aug; 70(2):301-6. PubMed ID: 8236139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of crosslinking on the structure of solubilized fibrin degradation products in whole plasma.
    Carroll RC; Lockhart MS; Taylor FB
    J Lab Clin Med; 1984 May; 103(5):695-703. PubMed ID: 6232329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue plasminogen activator in human megakaryocytes and platelets: immunocytochemical localization, immunoblotting and zymographic analysis.
    Jeanneau C; Sultan Y
    Thromb Haemost; 1988 Jun; 59(3):529-34. PubMed ID: 3142087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.